Malignancies in Deceased Organ Donors: The Spanish Experience
- PMID: 35421045
- DOI: 10.1097/TP.0000000000004117
Malignancies in Deceased Organ Donors: The Spanish Experience
Abstract
Background: To better define the risk of malignancy transmission through organ transplantation, we review the Spanish experience on donor malignancies.
Methods: We analyzed the outcomes of recipients of organs obtained from deceased donors diagnosed with a malignancy during 2013-2018. The risk of malignancy transmission was classified as proposed by the Council of Europe.
Results: Of 10 076 utilized deceased donors, 349 (3.5%) were diagnosed with a malignancy. Of those, 275 had a past (n = 168) or current (n = 107) history of malignancy known before the transplantation of organs into 651 recipients. Ten malignancies met high-risk criteria. No donor-transmitted cancer (DTC) was reported after a median follow-up of 24 (interquartile range [IQR]: 19-25) mo. The other 74 donors were diagnosed with a malignancy after transplantation. Within this group, 64 donors (22 with malignancies of high or unacceptable risk) whose organs were transplanted into 126 recipients did not result in a DTC after a median follow-up of 26 (IQR: 22-37) mo, though a prophylactic transplantectomy was performed in 5 patients. The remaining 10 donors transmitted an occult malignancy to 16 of 25 recipients, consisting of lung cancer (n = 9), duodenal adenocarcinoma (n = 2), renal cell carcinoma (n = 2), extrahepatic cholangiocarcinoma (n = 1), prostate cancer (n = 1), and undifferentiated cancer (n = 1). After a median follow-up of 14 (IQR: 11-24) mo following diagnosis, the evolution was fatal in 9 recipients. In total, of 802 recipients at risk, 16 (2%) developed a DTC, which corresponds to 6 cases per 10 000 organ transplants.
Conclusions: Current standards may overestimate the risk of malignancy transmission. DTC is an infrequent but difficult to eliminate complication.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
The authors declare no funding or conflicts of interest.
Comment in
-
Donor Cancer Transmission: Focusing on the Evidence.Transplantation. 2022 Sep 1;106(9):1728-1729. doi: 10.1097/TP.0000000000004118. Epub 2022 Apr 1. Transplantation. 2022. PMID: 35417114 No abstract available.
References
-
- Global Observatory on Donation and Transplantation. Global Observatory on Donation and Transplantation. 2020. Available at http://www.transplant-observatory.org/ . Accessed December 15, 2021.
-
- de la Rosa G, Domínguez-Gil B, Matesanz R, et al. Continuously evaluating performance in deceased donation: the Spanish quality assurance program. Am J Transplant. 2012;12:2507–2513.
-
- Irish GL, Coates PT, Clayton PA. Cancer post kidney transplant: the question of risk. J Nephrol. 2020;33:1129–1131.
-
- Nalesnik MA, Woodle ES, Dimaio JM, et al. Donor-transmitted malignancies in organ transplantation: assessment of clinical risk. Am J Transplant. 2011;11:1140–1147.
-
- Advisory Committee on the Safety of Blood, Tissues and Organs. Transplantation of organs from deceased donors with cancer or a history of cancer. 2014. Revised December 2020. Available at https://assets.publishing.service.gov.uk/government/uploads/system/uploa... . Accessed 15, December 2021.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous